Fernández-Polo Aurora, Melendo-Perez Susana, Larrosa Escartin Nieves, Mendoza-Palomar Natalia, Frick Marie Antoinette, Soler-Palacin Pere
Pharmacy Department, Hospital Infantil, Institut de Recerca Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Infantil, Institut de Recerca Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
Antibiotics (Basel). 2024 May 30;13(6):511. doi: 10.3390/antibiotics13060511.
Actions to reduce and optimize antimicrobial use are crucial in the management of infectious diseases to counteract the emergence of short- and long-term resistance. This is particularly important for pediatric patients due to the increasing incidence of serious infections caused by resistant bacteria in this population. The aim of this study was to evaluate the impact of a pediatric antimicrobial stewardship program (PROA-NEN) implemented in a Spanish tertiary hospital by assessing the use of systemic antimicrobials, clinical indicators, antimicrobial resistance, and costs. In this quasi-experimental, single-center study, we included pediatric patients (0-18 years) admitted to specialized pediatric medical and surgical units, as well as pediatric and neonatal intensive care units, from January 2015 to December 2019. The impact of the PROA-NEN program was assessed using process (consumption trends and prescription quality) and outcome indicators (clinical and microbiological). Antibiotic prescription quality was determined using quarterly point prevalence cross-sectional analyses. Total antimicrobial consumption decreased during the initial three years of the PROA-NEN program, followed by a slight rebound in 2019. This decrease was particularly evident in intensive care and surgical units. Antibiotic use, according to the WHO Access, Watch and Reserve (AWaRe) classification, remained stable during the study period. The overall rate of appropriate prescription was 83.2%, with a significant increase over the study period. Clinical indicators did not substantially change over the study period. Direct antimicrobial expenses decreased by 27.3% from 2015 to 2019. The PROA-NEN program was associated with reduced antimicrobial consumption, improved appropriate use, and decreased costs without compromising clinical and/or microbiological outcomes in patients.
减少和优化抗菌药物使用的措施对于传染病管理至关重要,以应对短期和长期耐药性的出现。由于该人群中耐药菌引起的严重感染发病率不断上升,这对儿科患者尤为重要。本研究的目的是通过评估全身用抗菌药物的使用、临床指标、抗菌药物耐药性和成本,来评估在一家西班牙三级医院实施的儿科抗菌药物管理计划(PROA-NEN)的影响。在这项准实验性单中心研究中,我们纳入了2015年1月至2019年12月期间入住儿科专科医疗和外科病房以及儿科和新生儿重症监护病房的儿科患者(0至18岁)。使用过程指标(消费趋势和处方质量)和结果指标(临床和微生物学指标)评估PROA-NEN计划的影响。使用季度现患率横断面分析确定抗生素处方质量。在PROA-NEN计划实施的最初三年中,抗菌药物总消费量有所下降,随后在2019年略有反弹。这种下降在重症监护病房和外科病房尤为明显。根据世界卫生组织的“准入、观察和储备”(AWaRe)分类,抗生素使用在研究期间保持稳定。适当处方的总体比例为83.2%,在研究期间显著增加。临床指标在研究期间没有实质性变化。从2015年到2019年,直接抗菌药物费用下降了27.3%。PROA-NEN计划与抗菌药物消费量减少、使用合理性提高和成本降低相关,且不影响患者的临床和/或微生物学结果。